Compare RIVN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIVN | BIIB |
|---|---|---|
| Founded | 2009 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 24.2B |
| IPO Year | 2021 | 1991 |
| Metric | RIVN | BIIB |
|---|---|---|
| Price | $14.29 | $177.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 20 | 24 |
| Target Price | $16.50 | ★ $181.77 |
| AVG Volume (30 Days) | ★ 27.9M | 1.6M |
| Earning Date | 02-12-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 10.97 |
| Revenue | $5,835,000,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $12.15 | $3.61 |
| Revenue Next Year | $26.95 | N/A |
| P/E Ratio | ★ N/A | $16.32 |
| Revenue Growth | ★ 28.21 | 4.77 |
| 52 Week Low | $10.36 | $110.04 |
| 52 Week High | $22.69 | $190.20 |
| Indicator | RIVN | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 26.10 | 53.90 |
| Support Level | $15.12 | $170.85 |
| Resistance Level | $15.56 | $176.14 |
| Average True Range (ATR) | 0.64 | 5.01 |
| MACD | -0.30 | 0.49 |
| Stochastic Oscillator | 8.20 | 77.13 |
Rivian is a battery electric vehicle automaker that sells its vehicles in the US and Canada. The company also develops electronic control units and related software for autos in a joint venture with Volkswagen. Rivian has multiple vehicles in its fleet, which include a luxury truck and full-size SUV and a delivery van. The company also plans to begin selling a midsize SUV in 2026. Total deliveries were nearly 52,000 in 2024. Rivian is also developing autonomous driving software to be used in its vehicles.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).